Texas Bank & Trust Co Purchases Shares of 712 Thermo Fisher Scientific Inc. (NYSE:TMO)

Texas Bank & Trust Co purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 712 shares of the medical research company’s stock, valued at approximately $370,000.

Several other large investors have also recently bought and sold shares of the stock. Tidal Investments LLC raised its holdings in Thermo Fisher Scientific by 36.9% in the 4th quarter. Tidal Investments LLC now owns 80,346 shares of the medical research company’s stock valued at $41,798,000 after acquiring an additional 21,643 shares during the period. TrinityPoint Wealth LLC grew its position in shares of Thermo Fisher Scientific by 7.1% during the 4th quarter. TrinityPoint Wealth LLC now owns 4,242 shares of the medical research company’s stock worth $2,207,000 after purchasing an additional 280 shares in the last quarter. Two Star Manager LLC grew its position in shares of Thermo Fisher Scientific by 63.6% during the 4th quarter. Two Star Manager LLC now owns 19,793 shares of the medical research company’s stock worth $10,297,000 after purchasing an additional 7,693 shares in the last quarter. Strive Asset Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $396,000. Finally, Tema Etfs LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $1,318,000. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 over the last quarter. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $412.15 on Monday. The company has a fifty day moving average price of $453.88 and a 200-day moving average price of $509.89. The company has a market capitalization of $155.58 billion, a P/E ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the firm earned $5.11 earnings per share. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.09%.

Analyst Ratings Changes

A number of brokerages have issued reports on TMO. UBS Group decreased their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Royal Bank of Canada decreased their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Argus reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Finally, Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.